Helus Pharma Shares Fall 21% Despite Phase 3 HLP003 Trial Meeting Primary Endpoint

Helus Pharma (NASDAQ:HELP) shares dropped 21% despite positive Phase 3 trial results for HLP003 in treating major depressive disorder. The trial met primary and secondary endpoints, showing significant improvement in depression symptoms compared to placebo. The company plans to release further results in late 2027.

Original reporting
Published Nov 16, 2026, 1:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 2:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Helus Pharma Shares Fall 21% Despite Phase 3 HLP003 Trial Meeting Primary Endpoint — source image
Decision brief

The 30-second read

$HELPBearishHigh
01

Why it matters

The Phase 3 APPROACH trial met its primary efficacy endpoint, yet the stock fell 21% as investors weighed commercial and safety considerations.

02

Market read

The announcement triggered a sharp intra‑day sell‑off, highlighting the sensitivity of biotech stocks to trial outcomes.

03

What to watch

Safety profile details and upcoming Phase 3 EMBRACE results could mitigate current concerns.

Relevance 8/10Novelty 9/10Timing: today

Background

Helus Pharma (NASDAQ:HELP) is a clinical‑stage biotech focused on novel treatments for major depressive disorder.

Company-level read

Ticker impact

$HELPBearishHigh confidence
Context

Helus Pharma reported Phase 3 trial results for HLP003, meeting primary endpoint but shares fell 21% on the news.

Expected impact

likely continued pressure as investors reassess commercial potential after the steep sell‑off.

Evidence & confidence

The market already reacted with a 21% decline; further downside is possible if investors view safety signals or market expectations as unmet.

Market effects

The result may influence sentiment toward other biotech firms developing depression therapies.

Limited to US‑listed biotech and pharma stocks.

Modest; primarily affects investors focused on mental‑health drug pipelines.

Counterpoint

The trial met its primary endpoint with strong statistical significance, suggesting upside if the market overreacts to the price drop.

Key entities

  • Helus Pharma Inc.

    US‑listed biotech developing HLP003 for depression.

Related articles

$HELPMed

HELP Stock Slides As Suicide Attempt Overshadows Strong Late-stage Depression Trial Data

HELP stock declined despite positive late-stage trial data for its depression drug, HLP003. The drug showed significant improvements in patients, with 56% seeing at least a 50% improvement at six weeks. Analysts like Lucid Capital raised their price target to $79, citing strong results, while Jefferies and Barclays maintained 'Buy' and 'Overweight' ratings, respectively. Retail sentiment on Stocktwits turned 'extremely bullish'.

$HELPMedAI 8/10

Helus Pharma falls 10.5% despite positive HLP003 trial

Helus Pharma (HELP) reported positive results for its experimental drug HLP003, meeting the primary endpoint in a late-stage depression trial. Despite this, shares fell 10.5% to $7.94, with three serious adverse events disclosed. Analysts noted strong efficacy and no fundamental reason for the decline. The company is also developing HLP004 for anxiety and expects to identify an HLP005 candidate in late 2027.

MedAI 8/10

Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression

Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.

HighAI 8/10

Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump

Helus Pharma reported that its psychedelic drug, HLP003, showed significant improvement in depression symptoms in a late-stage trial. The drug, a modified version of psilocin, is designed to be used with standard antidepressants. The company's shares rose over 20% in premarket trading. According to Helus, 56.3% of patients treated with HLP003 saw their symptoms cut by at least half, compared with 28.2% on placebo.